(2R,4S)-1-Tert-Butoxycarbonyl-4-Methylpyrrolidine-2-Carboxylic Acid

Production-scale evaluation of (2R,4S)-1-tert-butoxycarbonyl-4-methylpyrrolidine-2-carboxylic acid confirms its primary utility as a chiral intermediate in synthetic pathways where stereochemical integrity of the 4-methyl substituent directly governs downstream pharmacological activity. The Boc-protected pyrrolidine scaffold undergoes ring-opening, amide coupling, and deprotection sequences on multi-kilogram batches within reactor trains rated for −15 °C to 120 °C jacket temperature range. In a documented production campaign utilizing a 500 L glass-lined reactor, coupling with 4-fluoroaniline via HATU activation in dimethylformamide at 0–5 °C proceeded to 94.6% conversion by HPLC peak area within 4 hours. Residual (2R,4S)-configured starting material remaining at 3.2 mol% was found to co-crystallize with the desired amide product, requiring a toluene/n-heptane anti-solvent recrystallization at a controlled cooling rate of 0.25 °C/min between 50 °C and 20 °C to achieve diastereomeric purity exceeding 99.5% de as verified by chiral SFC analysis. Operational boundaries emerge at the deprotection stage: batch records indicate that telescoping the trifluoroacetic acid-mediated Boc cleavage without isolation of the intermediate amide leads to epimerization at C2 at a rate of 0.15% per hour at 22 °C, rendering the process unsuitable for extended hold times beyond 6 hours post-quench.

When Chirality at the Pyrrolidine 4-Position Dictates Thrombin Inhibition Potency

The (2R,4S)-configured 4-methylpyrrolidine-2-carboxylic acid core serves as a critical proline surrogate in the assembly of peptidomimetic thrombin inhibitors. Coupling the Boc-protected acid to a P2-arginine mimetic building block in the presence of EDCI and 1-hydroxybenzotriazole in dichloromethane at −10 °C — conditions selected to suppress diketopiperazine formation that consumes 8–12% of the dipeptide product at ambient temperature — yields the protected dipeptide segment. Following TFA-mediated N-Boc removal, the exposed secondary amine undergoes reductive amination with a benzylsulfonyl-substituted aldehyde under sodium triacetoxyborohydride in 1,2-dichloroethane containing 3% v/v acetic acid, a protocol deliberately formulated to avoid over-alkylation at the pyrrolidine nitrogen observed with sodium cyanoborohydride in methanol. Activity data from fluorogenic substrate cleavage assays (tosyl-Gly-Pro-Arg-AMC, excitation 380 nm, emission 460 nm) reveal that the (2R,4S)-methyl isomer exhibits a K_i value of 0.8 nM against human α-thrombin, while the corresponding (2S,4S)-diastereomer records 24 nM under identical buffer conditions (50 mM Tris, 150 mM NaCl, 0.1% PEG 6000, pH 7.8 at 25°C). The 30-fold potency differential is attributed to the pseudo-equatorial disposition of the 4-methyl group, which locks the pyrrolidine ring into an envelope conformation that pre-organizes the P3 benzylsulfonyl moiety for optimal S3 pocket occupancy as confirmed by co-crystal structures deposited under PDB codes 1OYT and 1OOK. On pilot scale, a campaign producing 18.7 kg of the final thrombin inhibitor API documented no process-related impurity exceeding 0.10 area% according to ICH Q3A(R2) thresholds when the starting (2R,4S)-acid Lot Analysis Certificate reported enantiomeric excess above 99.8% by chiral HPLC on a Chiralpak AD-H column (hexane/ethanol/trifluoroacetic acid 90:10:0.1). Process failure modes recorded during this campaign included a batch aborted at the amide bond formation stage when Karl Fischer titration detected 0.18% w/w water in the dimethylformamide charge, which suppressed HATU activation efficiency and stalled conversion at 71%.

Chiral stationary phase-based analytical and preparative separations dedicated to resolving N-Boc-4-methylproline enantiomers and diastereomers routinely employ the (2R,4S)-isomer as the reference standard for method qualification. A validated normal-phase HPLC method using a Chiralpak IA column (250 × 4.6 mm, 5 μm particle size) with a mobile phase of n-hexane, isopropanol, and methanesulfonic acid (95:5:0.1 v/v/v) at 1.0 mL/min achieves baseline resolution (R_s = 2.8) between the (2R,4S) and (2S,4R) enantiomers within 18 minutes, with a detection limit of 0.02 μg/mL at 210 nm established per ICH Q2(R1) guidelines. The analytical reference standard lot used for system suitability testing requires a minimum purity assignment of 99.5% w/w determined by mass balance, with residual solvent content quantified by headspace GC-FID against USP <467> Method IV acceptance criteria. Preparative-scale chiral SFC resolution operates at a feed concentration of 150 mg/mL in methanol on a Chiralpak IC column (250 × 30 mm, 5 μm) with 35% methanol-modified CO₂ at a total flow of 80 g/min and a column backpressure of 150 bar, processing 4.2 kg of racemic N-Boc-4-methylproline per 24-hour cycle to yield the (2R,4S)-enantiomer in 42.3% isolated recovery with 99.9% ee. Published data for this specific configuration’s solubility in supercritical CO₂-methanol binary mixtures at varying modifier concentrations remains limited; phase behavior screening at 40°C and 100–200 bar is recommended before committing to production-scale SFC conditions.

Evaluating Pyrrolidine Scaffold Rigidity in Hepatitis C NS3/4A Protease Inhibitor Design

Incorporation of the (2R,4S)-1-Boc-4-methylproline building block into macrocyclic acylsulfonamide inhibitors targeting the HCV NS3/4A serine protease exploits the conformationally constrained 4-methyl substitution to reduce entropic penalty upon binding to the S2 subsite. The synthesis proceeds via solution-phase Boc-deprotection of the pyrrolidine acid with 4 M hydrogen chloride in 1,4-dioxane, followed by coupling to a previously elaborated P1-P3 macrocyclic acid fragment using propanephosphonic acid anhydride (T3P, 50% w/w in ethyl acetate) and diisopropylethylamine in acetonitrile at 0 °C, conditions selected to avoid the epimerization of the cyclopropyl acyl sulfonamide warhead that is susceptible to alkoxide-mediated racemization under standard carbodiimide protocols. After aqueous workup at pH 4.5 and extractive isolation into methyl tert-butyl ether, the coupling product is crystallized from ethanol/water (1:1 v/v) at a seeding temperature of 42 °C to yield a uniform crystalline solid with a melting point of 178–180 °C (DSC onset, heating rate 10 °C/min) and XRPD diffractogram matching Form A previously registered in the drug master file. NS3 inhibition potency measured using a FRET-based assay (substrate Ac-Asp-Glu-Dap(QXL520)-Glu-Glu-Abu-ψ-[COO]-Ala-Ser-Cys(5-FAM)-NH₂) delivered IC₅₀ values of 0.12 nM for the (2R,4S)-methyl diastereomer versus 3.1 nM for the (2S,4R)-methyl analog under identical assay conditions (assay buffer: 50 mM HEPES, 100 mM NaCl, 5 mM DTT, 0.05% n-dodecyl-β-D-maltoside, pH 7.0 at 30 °C). Replicability of this stereochemical advantage depends on the absolute configuration at C2: molecular modeling on the published genotype 1b NS3 protease structure (PDB 3LON) indicates that inverting the C2 stereocenter while retaining (4S)-methyl collapses the macrocyclic ring geometry, displacing the P2 methyl group from the lipophilic pocket lined by His57, Arg155, and Ala156 by an estimated 1.7 Å.

Synthetic methodologies directed at constrained peptidomimetics for integrin α_vβ₃ antagonism utilize the (2R,4S)-1-Boc-4-methylproline as a proline replacement in RGD-mimetic cyclic pentapeptides. On-resin cyclization of the linear pentapeptide sequence H-Asp(OtBu)-D-Phe-Lys(Boc)-Arg(Pbf)-(2R,4S)-4-methylproline-OH proceeds following Fmoc-solid-phase peptide synthesis on a 2-chlorotrityl chloride resin preloaded at 0.8 mmol/g. The peptide-resin is subjected to global side-chain deprotection with a cocktail of TFA, triisopropylsilane, and water (95:2.5:2.5 v/v/v) for 2.5 hours at room temperature, followed by precipitation from cold diethyl ether. Crude linear peptide cyclization employs diphenylphosphoryl azide and sodium bicarbonate in DMF at a substrate concentration of 3 mM to minimize dimerization, a concentration established through systematic dilution studies tracking the dimer-to-monomer ratio by RP-HPLC (C18, 150 × 4.6 mm, gradient from 5% to 65% acetonitrile in 0.1% aqueous TFA over 30 minutes). The monomer:cyclodimer ratio shifts from 0.8:1 at 30 mM to 12:1 at 3 mM, necessitating batch process volumes exceeding 120 L per campaign for multi-gram API delivery. Analytical assessment of the product cyclic peptide by LC-HRMS (Q-TOF, ESI positive) confirms a monoisotopic mass deviation of <1.2 ppm from the theoretical value. Vitronectin receptor binding affinity, quantified via displacement of biotinylated vitronectin from immobilized α_vβ₃ integrin in an ELISA format, returned an IC₅₀ of 0.45 nM — a value contingent on maintenance of the (4S)-pseudoequatorial methyl configuration; the cis-4-methylproline-containing cyclic peptide prepared via identical synthetic and cyclization conditions shows a 40-fold reduction in affinity, demonstrating the absolute requirement for trans-geometry at C2 and C4 for favorable interaction with the β-propeller domain metal-ion-dependent adhesion site.

Compatibility constraints pertinent to scale-up of the cyclization step include a documented sensitivity to residual palladium from Fmoc deprotection: palladium content quantified by ICP-MS above 5 ppm in the linear peptide intermediate leads to non-reproducible cyclization kinetics attributed to metal coordination to the arginine guanidino group. Recourse requires a metal scavenger treatment with N-acetyl-L-cysteine functionalized silica gel (2% w/w relative to crude peptide) in methanol/water prior to lyophilization.

What Are the Off-Target Receptor Liability Profiles When 4-Methyl Substitution Replaces Unsubstituted Proline in Bradykinin B₂ Antagonist Peptides?

The (2R,4S)-configured acid is sequentially integrated into the C-terminal tetrapeptide fragment of the bradykinin B₂ receptor antagonist icatibant analogue libraries. The building block is introduced via HBTU-mediated coupling to the resin-bound tripeptide fragment Phe-Arg(Pbf)-D-Tic under double-coupling protocol (4 equivalents each of acid, HBTU, and N-methylmorpholine in NMP, 45 minutes per coupling cycle) to ensure complete acylation of the sterically hindered D-1,2,3,4-tetrahydroisoquinoline-3-carbonyl amine. Following TFA cleavage and RP-HPLC purification to 98.5% UV purity (220 nm), the peptide is evaluated in a radioligand binding assay using [³H]-des-Arg¹⁰-kallidin against human B₂ receptor expressed in Chinese hamster ovary cell membranes. Binding affinity (K_i 0.32 nM) obtained for the (2R,4S)-4-methylproline-containing analogue is statistically indistinguishable from the parent peptide incorporating unsubstituted L-proline (K_i 0.28 nM), suggesting that the 4-methyl substituent achieves the desired conformational restriction without perturbing the peptide backbone trajectory required for B₂ receptor interaction — a finding independently corroborated by solution NMR structure determination in DPC micelle medium (Bruker AVANCE III HD 800 MHz, ¹H-¹H NOESY mixing time 200 ms). In contrast, antagonist screening against the structurally homologous B₁ receptor measured a 5.2-fold increase in K_i relative to the des-methyl parent, indicating that the 4-methyl group introduced a subtle steric clash in the B₁ orthosteric site not present in the B₂ binding pocket; molecular dynamics simulations (AMBER ff19SB force field, 500 ns production trajectory) point to a steric conflict with B₁ Tyr⁹⁶ that is absent at B₂ Thr⁹⁸. This selectivity shift, confirmed across three independent binding assay replicates, represents an exploitable differentiation vector for B₂-over-B₁ antagonist design.